



CLASSIFICATION: PARTNER BRIEF

AUDIENCE: QUALIFIED OPERATORS

SOURCES: 14+ NIH/PMC

GLOBAL SEMAGLUTIDE MARKET · 2025

\$34.52B

Growing to \$268.4B by 2030

US TELEHEALTH WEIGHT-LOSS MARKET

\$6.9B

TRT market reaching \$3.51B by 2033

GLP-1 PATIENTS STILL ACTIVE AT 12 MO.

76.9%

NIH/PMC · n=51,247 real-world patients

THE GLP-1 AFFILIATE MARKET IS PAYING YOU ONCE AND KEEPING THE REST.

We pulled the affiliate commission data on 30+ telehealth programs. Here is what they actually pay — and what we pay instead.

PATIENT LTV

\$5,382

18 months at \$299/mo

INDUSTRY PAYS YOU

\$175–250

Once. Then nothing.

MAVRIC PAYS YOU

\$1,521

Across the same 18 months

00 — BEFORE THE MATH

YOU CAN'T BUILD A BUSINESS ON SAND.

The largest research chemical company in the men's health space just closed its doors. **Peptide Sciences** — the dominant supplier for the gray-market GLP-1 and peptide economy — shut down operations under compounding FDA scrutiny. They weren't an outlier. They were the market.

FDA ENFORCEMENT — ACCELERATING

The gray-market GLP-1 play is over. What's left is the compliant infrastructure play.

Every affiliate, coach, influencer, and wellness entrepreneur who built income on research chemical suppliers or unregulated compounders is one enforcement letter away from zero. The FDA has issued warning letters to **30+ telehealth companies**, shuttered the largest gray-market supply chains, and signaled ongoing enforcement against any company claiming their product is "the same active ingredient as Ozempic or Wegovy." [Source: FDA.gov, Feb 2026] Building a business from a research chemical website is building a house on sand. The ground shifts — they close the doors — and you have nothing.

Peptide Sciences	Closed operations. Largest gray-market research chemical supplier for GLP-1 and peptide economy. FDA scrutiny forced shutdown.
30+ Telehealth Co's	FDA Warning Letters issued Feb 2026. Violations: parallel branded domains, "same active ingredient" claims, unlicensed compounding partners.
MEDVi	FDA Warning Letter #721455. Class action lawsuits. Fake doctor personas, affiliate email violations, TCPA class action. Still operating under cloud.
Gray-market compounders	503B non-compliance crackdown ongoing. FDA has made clear: patient-specific individualization is the line. Bulk compounding without it is the target.

MAVRIC MEN — BUILT FOR WHAT COMES NEXT

MAVRIC is the infrastructure that survives the shake-out.

- LegitScript certified telehealth
- Real licensed physicians — real prescriptions
- No gray-market supply chain exposure
- Available 50 states (state-conditional)
- State-licensed 503A compounding pharmacy
- Zero "same active ingredient" claims
- FTC-compliant affiliate structure by design
- The thing the shuttered companies weren't

01 — THE MARKET YOU'RE ENTERING

THE MARKET ISN'T SHRINKING. IT'S CONSOLIDATING.

As gray-market operators get forced out, the demand doesn't disappear — it flows to compliant infrastructure. The GLP-1 and men's health telehealth market is one of the fastest-growing sectors in medicine. The enforcement wave doesn't kill the opportunity. **It hands the market to whoever built it right.**

<p>\$34.52B</p> <p>Global semaglutide market, 2025 [Grand View Research]</p>	<p>\$268.4B</p> <p>GLP-1 analogues market projection, 2030 [Fortune Business Insights]</p>
<p>\$6.9B</p> <p>US telehealth weight-loss market [GlobeNewsWire]</p>	<p>\$3.51B</p> <p>TRT market by 2033 from \$1.78B today [SkyQuest]</p>
<p>\$725M</p> <p>Hims & Hers weight-loss division alone, 2025 [Fierce Healthcare]</p>	<p>76.9%</p> <p>GLP-1 telehealth patients still active at 12 months [NIH/PMC PMC11589532, n=51,247]</p>
<p>30+</p> <p>Telehealth affiliate programs paying one-time CPA only.</p> <p>Every single one. No exceptions. They take your patient, keep 18 months of revenue, and pay you once. That's not a partnership. That's an acquisition fee.</p>	<p>0 → 1</p> <p>Unlimited recurring commissions — 50% of net profit on every customer you refer, for life. Until now.</p> <p>Zero programs offered true recurring commissions — 50% of net profit per referral, for the life of that customer — before MAVRIC. That changes here.</p>

02 — THE MATH THEY DON'T SHOW YOU

A patient subscribes to a compounded GLP-1 program at **\$299/month**. Real-world telehealth retention data shows they stay active for an average of 18 months. Total revenue that single patient generates: **\$5,382**.

<p style="text-align: center; font-size: 0.8em; margin: 0;">INDUSTRY MEDIAN</p> <p style="text-align: center; font-weight: bold; margin: 5px 0;">HIMS & HERS — INDUSTRY STANDARD</p> <p style="text-align: center; font-size: 2em; font-weight: bold; margin: 10px 0;">\$175–250</p> <p style="text-align: center; font-size: 0.7em; margin: 0;">One-time payout. Paid once. Ever. Then \$0/month for the next 17 months.</p>	<p style="text-align: center; font-size: 0.8em; margin: 0;">MAVRIC MEN</p> <p style="text-align: center; font-weight: bold; margin: 5px 0;">MAVRIC MEN — 50% NET PROFIT FOR LIFE</p> <p style="text-align: center; font-size: 2em; font-weight: bold; margin: 10px 0;">\$1,521</p> <p style="text-align: center; font-size: 0.7em; margin: 0;">Paid monthly. Across all 18 months. Same patient.</p>
---	--

COMPANY	PRODUCT	COMMISSION	RECURRING?
SkinnyRx	Compounded GLP-1	\$500–600 CPA	No
TrimRx	Compounded GLP-1	\$500–600 CPA	No
MEDVi	Semaglutide / Tirzepatide	\$300–500 CPA	No
Eden Health	Weight care	\$300–400 CPA	No
ShedRx	GLP-1 + coaching	\$350 CPA	No
Fella Health	Men's GLP-1	\$200–350 CPA	No
Hims & Hers	GLP-1 + multispecialty	\$175–250 CPA	No
Ro	GLP-1	\$50–75 CPA	No
Henry Meds	Semaglutide	\$25 CPA	No
Noom	Weight loss	\$15 CPA	No
Claya	Compounded GLP-1	\$125 total	Stops at month 3*
TeleWellnessMD	GLP-1 + hormones	10% of gross	Yes — \$360/yr*
T2D.com	GLP-1	\$15/month flat	Yes — \$180/yr*
FancyMeds	GLP-1	Up to 40% (MLM)	MLM structure
MAVRIC MEN	GLP-1 / TRT / Longevity	50% of net profit — for life	Yes — \$1,014/yr base

*The only two true-recurring industry programs pay \$180–360 per year, per patient. MAVRIC pays \$1,014/year at base case (12-month retention) and \$1,521 at the 18-month average. Every company above pays you once and keeps the monthly revenue forever. No cap. No volume minimum. No downline to build.

03 — WHAT ONE PATIENT IS ACTUALLY WORTH

Retention data: NIH/PMC study, n=51,247 real-world GLP-1 telehealth patients. 76.9% still enrolled at 12 months. Hims & Hers internal data: 75% active at 6 months. (Source: PMC11589532, Hims investor disclosures.)

SCENARIO	AVG. MONTHS ACTIVE	STANDARD \$300 CPA EARNS	MAVRIC 50% NET PROFIT EARNS	DIFFERENCE
Pessimistic	7 months	\$300	\$591	+97%
Base case	12 months	\$300	\$1,014	+238%
Optimistic	18 months	\$300	\$1,521	+407%
TRT patients	15 months avg	\$300	\$1,268	+323%

SCALE IT UP — YOUR MONTHLY INCOME

The CPA model pays you once. After that, the company keeps every dollar. The MAVRIC model pays you **every single month** your patient stays active. The numbers below are what hits your account **every 30 days** — not a one-time total.

<p>10 ACTIVE PATIENTS</p> <p>\$845</p> <p>PER MONTH</p> <p>CPA model: \$3,000 once — then \$0/month</p>	<p>25 ACTIVE PATIENTS</p> <p>\$2,112</p> <p>PER MONTH</p> <p>CPA model: \$7,500 once — then \$0/month</p>	<p>50 ACTIVE PATIENTS</p> <p>\$4,225</p> <p>PER MONTH</p> <p>CPA model: \$15,000 once — then \$0/month</p>
--	--	---

At 50 active patients on the MAVRIC model, your monthly income is **\$4,225 — every month**, on patients you already referred. The CPA model paid you \$15,000 once. Then **nothing**. Across 12 months, MAVRIC pays \$50,700 on those same 50 patients. You earned \$15,000 with everyone else. You left \$35,700 behind.

Monthly income calculated at \$84.50/patient/month (base case: \$299/mo revenue x ~43% net margin after pharmacy/product COGS, affiliate earns 50% of that net profit). Retention data: NIH/PMC PMC11589532.

04 — THE MAVRIC PARTNER STRUCTURE

THE SPLIT	WHAT'S INCLUDED	CLINICAL INFRASTRUCTURE
<p>50%</p> <p>You earn 50% of the net profit of every customer you refer, for the life of that customer. Every month. No cap. No expiry. No volume minimum.</p>	<ul style="list-style-type: none"> → Co-branded MAVRIC landing pages → Full GHM CRM access → Marketing assets, scripts, email + SMS → Approved objection handling → Real-time commission dashboard → Monthly payouts, Net-30 hold → Training portal + live calls → Compliance module (FTC/FDA) 	<ul style="list-style-type: none"> → Real licensed physicians → State-licensed 503A pharmacy → LegitScript certified telehealth → GLP-1, TRT, longevity protocols → Available in 50 states (state-conditional) → No gray-market supply chain → HIPAA-compliant architecture → Built to survive the shake-out

INDIVIDUAL LICENSE	ORGANIZATIONAL LICENSE
<p>\$400</p> <p>Standard: \$999</p>	<p>\$997</p> <p>Standard: \$1,997</p>

THROUGH MAY 31, 2026 · BEYOND BIOHACKING CONFERENCE PRICING

mavric-conference.com/conference

— or scan the QR code —

You've seen the numbers. The question is how many patients you want to refer.

